Immuneering Stock (NASDAQ:IMRX)

Forecast Revenue Ownership Financials Chart

Previous Close

$4.00

52W Range

$1.00 - $4.69

50D Avg

$2.80

200D Avg

$2.06

Market Cap

$146.10M

Avg Vol (3M)

$1.27M

Beta

0.37

Div Yield

IMRX Company Profile

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jul 30, 2021

Website

IMRX Performance

IMRX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	$316.95K
Operating Income	$-64.07B	$-58.41M	$-51.74M
Net Income	$-61.04B	$-53.47M	$-49.28M
EBITDA	$-64.07B	$-58.06M	$-51.47M
Basic EPS	$-2.04K	$-1.88	$-1.87
Diluted EPS	$-2.04K	$-1.88	$-1.87

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 22Mar 06, 23 | 4:30 PM

Peer Comparison

Ticker	Company
RPID	Rapid Micro Biosystems, Inc.
CTKB	Cytek Biosciences, Inc.
RXST	RxSight, Inc.
OLMA	Olema Pharmaceuticals, Inc.
OBIO	Orchestra BioMed Holdings, Inc.
LRMR	Larimar Therapeutics, Inc.
CNTA	Centessa Pharmaceuticals plc
NVCT	Nuvectis Pharma, Inc.
TRML	Tourmaline Bio, Inc.